2026-2034年囊腫纖維化治療藥物全球市場規模、佔有率、趨勢和成長分析報告

囊腫纖維化治療市場規模預計將從 2025 年的 225.5 億美元成長到 2034 年的 862.3 億美元，2026 年至 2034 年的複合年成長率為 16.07%。

受疾病認知度提高和標靶治療進步的推動，全球囊腫纖維化治療市場正穩步成長。囊腫纖維化是一種主要影響肺部和消化器官系統的遺傳性疾病，需要長期治療和管理。製藥公司正大力投資研發，以推出針對致病基因突變的創新治療方法，進而改善患者的預後和平均壽命。

推動市場成長的主要動力是CFTR調變器療法的研發，這類療法著重於囊腫纖維化的根本病因，而非僅僅緩解症狀。這些先進的治療方法徹底改變了我們治療疾病的方式，並顯著改善了許多患者的生活品質。此外，診斷技術的進步和新生兒篩檢計畫的發展使得疾病的早期發現成為可能，從而能夠及時治療，並進一步增加了對有效療法的需求。

未來幾年，基因療法和個人化醫療的持續研究預計將對市場產生積極影響。生物技術的進步有望實現更精準的治療方法，以糾正導致囊腫纖維化的基因缺陷。此外，醫療保健領域投資的增加和支持性法規結構的完善將加速藥物研發，使全球患者更容易獲得先進的治療方法。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球囊腫纖維化治療藥物市場：依藥物類別分類

• 市場分析、洞察與預測
• CFTR調變器
• 胰酵素替代療法
• 祛痰藥
• 支氣管擴張劑

第5章 全球囊腫纖維化治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 吸入

第6章 全球囊腫纖維化治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球囊腫纖維化治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AbbVie Inc
  • F. Hoffmann-La Roche Ltd
  • Gilead
  • Novartis AG
  • Vertex Pharmaceuticals Incorporated
  • AIT（Advanced Inhalation Therapies）
  • Alaxia
  • Teva Pharmaceutical Industries Ltd
  • Merck & Co. Inc
  • Sionna Therapeutics
  • Alcresta Therapeutics Inc
  • AstraZeneca

The Cystic Fibrosis Therapeutics Market size is expected to reach USD 86.23 Billion in 2034 from USD 22.55 Billion (2025) growing at a CAGR of 16.07% during 2026-2034.

The Global Cystic Fibrosis Therapeutics Market is growing steadily due to increasing awareness of the disease and advancements in targeted therapies. Cystic fibrosis is a genetic disorder that primarily affects the lungs and digestive system, requiring long-term treatment and management. Pharmaceutical companies are investing heavily in research and development to introduce innovative therapies that address the underlying genetic mutations responsible for the condition, improving patient outcomes and life expectancy.

A major driver of market growth is the development of CFTR modulator therapies, which target the root cause of cystic fibrosis rather than simply managing symptoms. These advanced treatments have transformed the treatment landscape and significantly improved the quality of life for many patients. Additionally, improved diagnostic techniques and newborn screening programs are helping detect the disease earlier, enabling timely treatment and increasing demand for effective therapeutics.

In the coming years, the market is expected to benefit from continued research into gene therapies and personalized medicine approaches. Advances in biotechnology may lead to more precise treatments that correct the genetic defects responsible for cystic fibrosis. Furthermore, increasing healthcare investments and supportive regulatory frameworks are likely to accelerate drug development, making advanced therapies more accessible to patients worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• CFTR Modulators
• Pancreatic Enzyme Supplements
• Mucolytics
• Bronchodilators

By Route of Administration

• Oral
• Inhaled

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AbbVie Inc, F HoffmannLa Roche Ltd, Gilead, Novartis AG, Vertex Pharmaceuticals Incorporated, AIT Advanced Inhalation Therapies, Alaxia, Teva Pharmaceutical Industries Ltd, Merck amp Co Inc, Sionna Therapeutics, Alcresta Therapeutics Inc, AstraZeneca
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. CFTR Modulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Pancreatic Enzyme Supplements Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Mucolytics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Bronchodilators Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Inhaled Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CYSTIC FIBROSIS THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AbbVie Inc
  • 9.2.2 F. Hoffmann-La Roche Ltd
  • 9.2.3 Gilead
  • 9.2.4 Novartis AG
  • 9.2.5 Vertex Pharmaceuticals Incorporated
  • 9.2.6 AIT (Advanced Inhalation Therapies)
  • 9.2.7 Alaxia
  • 9.2.8 Teva Pharmaceutical Industries Ltd
  • 9.2.9 Merck & Co. Inc
  • 9.2.10 Sionna Therapeutics
  • 9.2.11 Alcresta Therapeutics Inc
  • 9.2.12 AstraZeneca